Brelovitug Phase 3 Win Opens U.S. First-Mover Door, But Surrogate Endpoint and Payer Scrutiny Loom

Brelovitug Meets Primary Endpoint in Phase 3 AZURE-1 Study

Mirum Pharmaceuticals announced that its investigational drug, brelovitug, met the primary endpoint in the Phase 3 portion of the AZURE-1 study for chronic hepatitis delta virus (HDV). Both the 300 mg once weekly and 900 mg once every four weeks subcutaneous dose arms achieved the combined endpoint of virologic response and ALT normalization at Week 24, with 56% and 45% of patients responding, respectively, compared to 0% in the delayed treatment arm (p<0.0001 for both). Additionally, 48-week data from the Phase 2b portion of AZURE-1 showed deepening viral suppression and increased rates of ALT normalization with longer-term treatment. Brelovitug maintained a favorable safety and tolerability profile. Mirum plans to submit a Biologics License Application (BLA) in H1 2027, targeting a potential U.S. commercial launch in Q4 2027.

• In the Phase 3 AZURE-1 study, brelovitug demonstrated significant efficacy at Week 24. The 300 mg QW arm showed 56% of patients achieving the primary endpoint (virologic response + ALT normalization), 86% achieving virologic response, and 63% achieving ALT normalization. The 900 mg Q4W arm reported 45% for the primary endpoint, 85% for virologic response, and 54% for ALT normalization, with both dose groups significantly outperforming the delayed treatment arm (p<0.0001).
• Extended 48-week data from the Phase 2b portion of AZURE-1 highlighted the sustained and deepening benefits of brelovitug. Patients continuing treatment showed enhanced viral suppression, with a greater proportion achieving HDV RNA below the lower limit of quantification and target not detected. Furthermore, rates of ALT normalization continued to increase, reinforcing the drug's potential for long-term disease control in chronic HDV.
• Brelovitug exhibited a consistent and favorable safety and tolerability profile across all dose groups through Week 24 in Phase 3 and Week 48 in Phase 2b, with no new safety signals identified. These positive results support Mirum's plan to submit a Biologics License Application (BLA) to the U.S. FDA in the first half of 2027, with an anticipated commercial launch in the U.S. by Q4 2027, following topline results from the AZURE-4 study later this year.

Addressing the Critical Unmet Need in Chronic Hepatitis Delta Virus

Chronic hepatitis delta (CHD) remains the most severe form of chronic viral hepatitis, characterized by rapid progression to cirrhosis, end-stage liver disease, and hepatocellular carcinoma. Despite recent therapeutic advances, significant challenges persist across both established and emerging treatment modalities.

• Limited efficacy of interferon-based therapy: Prior to bulevirtide, pegylated interferon-alpha (PEG-IFNα) represented the only treatment option for CHD. Sustained virological response rates reached only approximately 20–25%, and more than half of successfully treated patients experienced virological relapse after therapy cessation. Extending PEG-IFNα treatment duration to two years did not increase treatment success, as shown by the results of most clinical trials. Additionally, interferon carries an undesirable side effect profile — including flu-like symptoms, asthenia, weight loss, alopecia, thrombocytopenia, and leukopenia — that effectively contraindicates its use in patients with more advanced liver disease.

• Absence of a direct antiviral target within HDV: HDV does not encode any enzymatic function and is replicated by host RNA polymerases; it therefore has no replicative machinery of its own to be targeted by antivirals. The only requirement HDV has of HBV is the HBsAg coat for hepatocyte attachment and virion assembly, meaning HBV antivirals that decrease HBV-DNA while leaving HBsAg unaffected are of no avail in CHD.

• Unresolved questions around bulevirtide treatment duration and sustained response: While bulevirtide received conditional marketing authorization from the European Medicines Agency in July 2020 — subsequently converted to standard marketing authorization in July 2023 — the optimal duration of treatment has not yet been established. Sustained virological response could not be assessed in clinical trials because bulevirtide treatment was not discontinued in the studies. In real-world data from 114 patients, virologic breakthrough (defined as a >1 log-increase in HDV RNA after virologic response) was observed in 11 cases, and no patient lost hepatitis B surface antigen.

• Bile acid elevation as an on-treatment pharmacodynamic effect without predictive utility: Bulevirtide blocks NTCP, resulting in an asymptomatic increase in serum bile acid levels in most patients. However, bile acid increases during treatment were not associated with HDV RNA or ALT declines at any time point, and delta bile acid levels from baseline to Week 48 did not differ between virologic responders and non-responders. Bile acid level monitoring during and following bulevirtide treatment is thus not advised for clinical practice.

• Epidemiological underdiagnosis and unmet global prevalence data: An estimated 4.5–13% of HBsAg-positive individuals are infected with HDV globally, representing 12–72 million persons in absolute numbers. Understanding the true prevalence of HDV remains a challenge, and continued epidemiological surveillance is necessary to fully characterize the unmet need and guide therapeutic development strategies.

Brelovitug's Efficacy in the Pivotal AZURE-1 Phase 3 Study

Several clinical trials have evaluated therapeutic strategies for chronic hepatitis delta virus (HDV) infection, spanning combination antiviral regimens, entry inhibitors, and novel monoclonal antibodies. The studies below represent key evidence across distinct mechanisms of action and trial designs.

Brelovitug's Strong Phase 3: A New Hope for Chronic HDV

Chronic hepatitis delta virus (HDV) infection represents the most aggressive form of human viral hepatitis, leading to rapid progression of liver disease and a high unmet medical need. For decades, treatment options have been severely limited, with pegylated interferon-alpha offering only modest efficacy, achieving sustained virological responses in a small fraction of patients. The recent announcement regarding brelovitug's successful Phase 3 AZURE-1 study marks a pivotal moment for patients and clinicians grappling with this challenging disease.

Brelovitug demonstrated impressive efficacy, with 56% and 45% of patients achieving the combined endpoint of virologic response and ALT normalization at Week 24 in its two subcutaneous dosing arms, significantly outperforming the control group. This level of response positions brelovitug as a potentially transformative therapy, offering a substantial improvement over historical treatments. The convenience of subcutaneous administration, particularly the once-every-four-weeks option, could significantly enhance patient adherence and quality of life, a critical factor in managing chronic conditions.

However, as brelovitug moves towards regulatory submission, several factors will be key to its long-term success. While 48-week data from the Phase 2b portion showed deepening responses, the full long-term durability and safety profile from the larger Phase 3 cohort beyond 24 weeks will be crucial for establishing its place in therapy. The competitive landscape is also evolving, with bulevirtide already approved in Europe and demonstrating sustained efficacy over 96 weeks. Brelovitug will need to clearly differentiate itself, perhaps through its dosing convenience, specific safety profile, or real-world effectiveness. Detailed safety data from the Phase 3 study, beyond the 'favorable' summary, will be essential for regulatory bodies and prescribers. Ultimately, brelovitug's strong initial data offers a beacon of hope, promising a new era of more effective and patient-friendly treatment for chronic HDV.